MMP-9 level in patients with non-ST-segment elevation acute coronary syndrome as a result of treatment with different doses of atorvastatin


Дәйексөз келтіру

Толық мәтін

Ашық рұқсат Ашық рұқсат
Рұқсат жабық Рұқсат берілді
Рұқсат жабық Рұқсат ақылы немесе тек жазылушылар үшін

Аннотация

Background. Cardiovascular diseases are global medical problem. In the development of acute coronary events, including acute coronary syndrome (ACS), oxidative stress with an increased release of matrix metalloproteinases-9 (MMP-9) plays a critical role. However, the dynamics of MMP-9 level under the influence of different doses of statins in patients with ACS requires clarification. Objective. Evaluation of the oxidative stress indicators and MMP-9 levels in patients with non-ST segment elevation ACS (NSTE-ACS) depending on treatment with different doses of atorvastatin. Methods. In the conditions of the Kuban State Medical University, 68 patients with NSTE-ACS (mean age - 55.6±3.6 years) were examined. Study design: case series. All patients underwent ECG, determination of the troponin I, MMP-9, malondialdehyde (MDA) and sulfhydryl groups (SH-groups) levels, as well as the blood plasma content of stable NO metabolite - NO2. Results. Compared with patients with stable angina and the control group, in patients with NSTE-ACS against the background of oxidative stress (according to the SH-groups, MDA, and blood plasma NO2 levels), an increased level of proteolytic and inflammatory activity was revealed, which was confirmed by high MMP-9 concentration. Therapy with atorvastatin was accompanied by minimization of oxidative inflammation and a decrease in MMP-9 levels. Conclusion. The therapeutic effect of atorvastatin was dose-dependent with the greatest positive anti-inflammatory and antioxidant effect at a dose of 60 mg/day for 4 weeks.

Толық мәтін

Рұқсат жабық

Авторлар туралы

V. Gorban

Kuban State Medical University

Email: gorbanvv@mail.ru
Dr. Sci. (Med.), Head of the Department polyclinic therapy 4, Mitrofan Sedin str., Krasnodar 350063, Russian Federation

D. Kalashnik

Kuban State Medical University

Krasnodar, Moscow

Әдебиет тізімі

  1. Nielsen S.H., Mouton A.J., DeLeon-Pennell K.Y, et al. Understanding Cardiac Extracellular Matrix Remodeling to Develop Biomarkers of Myocardial Infarction Outcomes. Matrix Biol. 2019;75-76:43-57. doi: 10.1016/j.matbio.2017.12.001.
  2. Bloksgaard M., Lindsey M., Martinez-Lemus L.A. Extracellular matrix in cardiovascular pathophysiology. Am J Physiol Heart Circ Physiol. 2018;315(6):H168 7-90. Doi: 10.1152/ ajpheart.00631.2018.
  3. Legein B, Temmerman L., Biessen E.A.L., Lutgens E. Inflammation and immune system interactions in atherosclerosis. Cell Mol Life Sci. 2013; 70:3847-69.
  4. Cimmino G., Ragni M., Cirillo P, et al. C-reactive protein induces expression of matrix metalloproteinase-9: a possible link between inflammation and plaque rupture. Int J Cardiol. 2013;168:981-86. Doi: 10.1016/j. ijcard.2012.10.040.
  5. Dhawan V., Rather R.A. Association of Matrix Metalloproteinases with CVD: Functional Aspects. Proteases in Human Diseases, Springer, Singapore. 2017. P 473-96.
  6. Gregoli K.D., Johnson J.L. Role of Matrix Metalloproteinases in the Development and Progression of Atherosclerosis. Proteases in Human Diseases. Springer, Singapore, 2017. P 425-46.
  7. Говорин А.В., Рацина Е.В., Соколова Н.А., Фетисова Н.В. Показатели матриксной металлопротеиназы-9 и тканевого ингибитора металлопротеиназ-1 при остром трансмуральном инфаркте миокарда, осложненном аневризмой. Российский кардиологический журнал. 2014;7(111):87-90. Doi: 10.15829 /1560-4071-2014-7-87-90.
  8. Iyer R.P, Jung M., Lindsey M.L. MMP-9 signaling in the left ventricle following myocardial infarction. Am J Physiol Heart Circ Physiol. 2016;311(1):H190-8. doi: 10.1152/ajpheart.00243.2016
  9. Francis Stuart S.D., De Jesus N.M., Lindsey M.L., Ripplinger C.M. The crossroads of inflammation, fibrosis, and arrhythmia following myocardial infarction. J Mol Cell Cardiol. 2016;91:114-22. doi: 10.1016/j.yjmcc.2015.12.024.
  10. Lombardi M., Mantione M.E., Baccellieri D., et al. P2X7 receptor antagonism modulates IL-1fi and MMP9 in human atherosclerotic vessels. Sci Rep. 2017;7:4872. doi: 10.1038/s41598-017-05137-y.
  11. Попов М.А., Шумаков Д.В., Зыбин Д. И. и др. Феномен роли коллагена IV типа и матриксной металлопротеиназы 9 типа в ремоделировании миокарда левого желудочка при ишемической болезни сердца. Российский кардиологический журнал. 2019;24(8):83-7. doi: 10.15829/1560-4071-2019-8-83-87.
  12. Ma Y., Iyer R.P, Jung M., et al. Cardiac Fibroblast Activation Post-Myocardial Infarction: Curr. Knowledge Gaps Trends Pharmacol. Sci. 2017;38(5):448-58. Doi: 10.1016/j. tips.2017.03.001.
  13. De Leon-Pennell K.Y, Meschiari C.A., Jung M., Lindsey M. L. Matrix Metalloproteinases in Myocardial Infarction and Heart Failure. Prog Mol Biol TranslSci. 2017;147:75-100. Doi: 10.1016/ bs.pmbts. 2017.02.001.
  14. Newby A.C. Metalloproteinase expression in monocytes and macrophages and its relationship to atherosclerotic plaque instability. Arterioscler Thromb Vasc Biol. 2008;28:2108-14. doi: 10.1161/ATVBAHA.108.173898
  15. Shirakabe A., Asai K., Hata N., et al. Immediate administration of atorvastatin decreased the serum MMP-2 level and improved the prognosis for acute heart failure. J Cardiol. 2012;59(3):374-82. doi: 10.1016/j.jjcc.2012.01.009.
  16. Белоусов Ю.Б., Леонова М.В., Смирнова Е.П. и др. Вазопротективная эффективность статинов у больных с каротидным атеросклерозом. Российский кардиологический журнал. 2007;5(67):51-6.
  17. Cevik C., Nugent K., Meyerrose G., et al. Rosuvastatin Therapy Does Not Affect Serum MMP-13 or TIMP- 1 levels in Hypercholesterolemic Patients. Tex Heart Inst J. 2011;38(3):229-33.
  18. Jager N.A., de Vries B.M.W., Hillebrands J.-L., et al. Distribution of Matrix Metalloproteinases in Human Atherosclerotic Carotid Plaques and Their Production by Smooth Muscle Cells and Macrophage Subsets. Mol Imag Biol. 2016;18(2):283-91. doi: 10.1007/s11307-015-0882-0.
  19. Камышников В.С. Справочник по клинико-биохимическим исследованиям и лабораторной диагностике. М., 2004. 920 с.
  20. Шенкман Б.С. Ломоносова Ю.Н., Немировская Т.Л. Нейрональная NO-синтаза-молекулярный гарант стабильности мышечного волокна. NO-зависимые сигнальные пути в активной и разгруженной мышце. Успехи физиологических наук. 2014;45(2):37-48.
  21. Toba H., Cannon P.L., Yabluchanskiy A., et al. Transgenic overexpression of macrophage matrix metalloproteinase-9 exacerbates age-related cardiac hypertrophy, vessel rarefaction, inflammation, and fibrosis. Am J Physiol Heart Circ Physiol. 2017;312(3):H375-83. Doi: 10.1152/ ajpheart.00633.2016.
  22. Tziakas D.N., Chalikias G.K., Parissis J.T., et al. Serum profiles of matrix metalloproteinases and their tissue inhibitor in patients with acute coronary syndromes. The effects of short-term atorvastatin administration. Int J Cardiol. 2004;94(2-3):269-77.
  23. Biankenberg S., Rupprecht H., Poirier O. Plasma Concentrations and Genetic Variation of Matrix Metalloproteinase 9 and Prognosis of Patients With Cardiovascular Disease. Circulation. 2003;107:1579-85.
  24. Angelini G, Flego D., Vinci R., et al. Matrix metalloproteinase-9 might affect adaptive immunity in non-ST segment elevation acute coronary syndromes by increasing CD31 cleavage on CD4+ T-cells. Eur Heart J. 2018;39:1089-97. doi: 10.1093/eurheartj/ehx684.
  25. Warnholtz A., Wendt M., August M., Munzel T Clinical aspects of reactive oxygen and nitrogen species. Biochem Soc Symp. 2004;71:121-33. doi: 10.1042/bss0710121.
  26. Tarin C., Gomez M., Calvo E., et al. Endothelial nitric oxide deficiency reduces MMP-13-mediated cleavage of ICAM-1 in vascular endothelium: a role in atherosclerosis. Arterioscler. Thromb Vasc Biol. 2009;29:27-32.
  27. Garvin P, Jonasson L., Nilsson L., Falk M., Kristenson M. Plasma Matrix Metalloproteinase-9 Levels Predict First-Time Coronary Heart Disease: An 8-Year Follow-Up of a Community-Based Middle Aged Population. PLoS One. 2015;10(9):e0138290. doi: 10.1371/journal. pone.0138290.
  28. Lindsey M.L. Assigning matrix metalloproteinase roles in ischaemic cardiac remodelling. Nat Rev Cardiol. 2018;15(8):471-79. Doi: 10.1038/ s41569-018-0022.

Қосымша файлдар

Қосымша файлдар
Әрекет
1. JATS XML
Жүктеу

© Bionika Media, 2020